In one retrospective analysis of patients (all ages) with newly diagnosed FLT3-mutated AML (median allelic frequency 0.03 [range, 0.01-0.09]), the best outcomes were observed in those who received a frontline FLT3 inhibitor and underwent subsequent HSCT, suggesting that this is an effective approach for fit patients with low-burden FLT3 mutations [60]. Here, FLT3 is linked to acute myeloid leukemia.